This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

hyperlink,10000

I HAVE EGPA AND A WAY FORWARD

https://gskpro-com-preprod-cf5.gdsgsk.com/en-us/products/nucala/about/,1000

Nucala HES
Nucala HES

NUCALA is indicated for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non-hematologic secondary cause.

 

NUCALA provides proven protection from flares1

Randomized, placebo-controlled trial

72%

Primary endpoint results: Proportion of patients who experienced HES flare(s)* during the 32-week study or withdrew. NUCALA 28% vs placebo 56%, P=0.002.

HES flare: Worsening of clinical signs/symptoms or increased eosinophils (on ≥2 occasions), resulting in an escalation/addition of oral corticosteroids (OCS) or cytotoxic or immunosuppressive therapy.

Identifying HES

Identifying HES

The definition, clinical manifestations, and more

Learn about HES

Shield icon

Flare reduction

Proportion of patients with flares and time to first flare

Review the data

Eosinophil reduction icon

Mechanism of action (MOA) and eosinophil reduction

See the results of NUCALA on eosinophil reduction

View MOA and eosinophil data

Checklist icon

Access & reimbursement

Rep icon

Request a Rep

Register Icon

Register for updates

Reference:

  1. Roufosse F, Kahn JE, Rothenberg ME, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;146(6):1397-1405.